Screening for BRCA1/2 gene mutations in breast and ovarian cancer using NGS technology could avoid a treatment cost of 42 million baht for patients with advanced breast cancer (37 million baht) or advanced ovarian cancer (5 million baht). This evidence concerns the gene BRCA1 and ovarian carcinoma.